Therapies for hidradenitis suppurativaAlthough hidradenitis suppurativa is a disease that is extremely impactful and burdensome several medical therapies have been proven to be effective and safe.
Five specialty pharmaceutical trends to watchApprovals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.
Remicade will now have a biosimilarExpert: Expectations are high that biosimilars can control overall biologic cost growth.
Biosimilar drugs appear comparable to brand-name counterpartsSystematic review provides comprehensive first look at TNF-alpha biosimilar treatments.
Hidradenitis suppurativa misunderstood and underdiagnosedMisconceptions about hidradenitis suppurativa (HS) prevent dermatologists and other clinicians from properly diagnosing and treating what one expert says is a “crippling disease.”
Biosimilar offers hope of lower-cost treatment of autoimmune diseasesHere's the latest on the second biosimilar in line to receive FDA approval.
Can you maintain response after biologic holiday?Melinda Gooderham, M.D., MSc, FRCPC Patients might stop taking their biologic medications for a variety of reasons. When patients do stop their biologic therapy, clinicians need to consider that some biologic therapies are better at recapturing response than others. learn more
New rheumatoid arthritis therapies are comingFour new drugs and a biosimilar should be on your radar.
Cholesterol-lowering agent leads list of most-prescribed drugsRosuvastatin (Crestor, AstraZeneca), a cholesterol-lowering agent, is currently the most-prescribed drug among the 100 most-prescribed and best-selling drugs in the United States. In the past 12 months, new prescriptions and refills for rosuvastatin have been estimated to amount to 23.7 million.
Drugs in Perspective: Otezla (apremilast)Otezla (apremilast), a small-molecule inhibitor of phosphodiesterase 4 (PDE4), was approved by FDA on March 21, 2014, for the treatment of adult patients with active psoriatic arthritis. On September 23, 2014, it was approved for a second indication, the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy